PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical
PA21-259、PHS 2021-2 NIH、CDC 和 FDA 小型企业创新研究补助金申请综合征集(母版 SBIR [R43/R44] 临床
基本信息
- 批准号:10601913
- 负责人:
- 金额:$ 20万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Project Summary
Our proposed effort addresses foodborne illness caused by pathogenic bacteria surviving inadequate
sanitization processes. Fresh sprouts are a known vehicle of foodborne illness due to industry reliance on an
insufficient process for disinfecting sprout seeds. The FDA acknowledges their recommended chlorine-based
(Cl) treatment inadequately eliminates bacterial pathogens4 and welcomes the development of new treatments.5
The objective of this SBIR is to develop and commercialize a novel organic sprout seed sanitizer based on an
AEMS Corp. proprietary technology called an Agent Delivery Matrix (ADM). Our sanitizing ADM are intentionally
composed entirely of Generally Recognized As Safe (GRAS) ingredients in order to be amenable with fast-track
FDA approval and to ensure food, worker, and environmental safety. Adoption of our sanitizing ADM could foster
a new era of environmentally friendly organic sprout production that lowers the incidence of sprout-related
foodborne illness, saves the grower time and money, enhances worker safety, and promotes the health-food
benefits of sprouts desired by consumers and producers.
We will demonstrate our treatment can be an effective replacement of Cl treatment through two primary Aims.
During Aim 1, we will validate ADM as an effective new approach to deliver GRAS sanitizers capable of killing
Escherichia coli. We will use a clinical isolate of the pathogenic E. coli O157:H7 throughout Phase I instead of
a surrogate bacterium to realistically validate the efficacy of our treatment. Combinatorial screens will yield a
library of sanitizing ADM materials for sprout seed sanitization. The most effective ADM will be studied in Aim 2
to sanitize sprout seeds in simulated industrial growing conditions at UC Davis. Since nearly all cases of sprout-
related foodborne illness originate from infected seed that is improperly sanitized, we will exercise a real-life
scenario for sprouting after intentionally infecting alfalfa seeds with E. coli O157:H7 to test for sanitation efficacy.
We will also evaluate germination rate and sprout yield to evaluate our treatment’s effects on sprout quality. Aim
2 imposes realistic conditions to accurately reflect industrial production of sprouts to facilitate adoption of our
technology and garner commercial interest.
Inadequate sanitization of sprout seeds will continue to jeopardize the safety and security of the food supply until
a new treatment is adopted. Successful completion of this SBIR Phase I project will lead to a new way to produce
sprouts safer for human consumption. Extension of ADM technology to other seed coatings and food processing
facility surfaces will improve the safety of other food products. Future research and development will extend the
ADM platform to other applications in human health and food safety. Funding will ensure the safety of food and
promote the integrity of the food supply by reducing the incidence of foodborne illness.
项目概要
我们提出的努力解决因病原菌存活不足而引起的食源性疾病
由于行业对食品的依赖,新鲜豆芽是一种已知的食源性疾病媒介。
FDA 承认其推荐的氯基消毒方法不足。
(Cl) 治疗不足以消除细菌病原体4,欢迎新疗法的开发5。
该 SBIR 的目标是开发并商业化一种基于
AEMS Corp. 的专有技术称为代理交付矩阵 (ADM) 我们的消毒 ADM 是有意设计的。
完全由公认安全 (GRAS) 成分组成,以便符合快速通道要求
FDA 批准并确保食品、工人和环境安全,采用我们的消毒 ADM 可以促进。
环保有机豆芽生产的新时代,降低豆芽相关疾病的发生率
食源性疾病,节省种植者的时间和金钱,提高工人的安全,并推广健康食品
消费者和生产者所期望的豆芽的好处。
我们将通过两个主要目标证明我们的治疗可以有效替代氯治疗。
在目标 1 期间,我们将验证 ADM 是一种有效的新方法,可提供能够杀死细菌的 GRAS 消毒剂
我们将在整个 I 阶段使用致病性大肠杆菌 O157:H7 的临床分离株,而不是大肠杆菌。
替代细菌来实际验证我们的治疗效果将产生一个结果。
用于芽苗种子消毒的消毒 ADM 材料库 将在目标 2 中研究最有效的 ADM。
在加州大学戴维斯分校的模拟工业生长条件下对豆芽种子进行消毒,因为几乎所有的豆芽案例都如此。
相关的食源性疾病源于未正确消毒的受感染种子,我们将在现实生活中进行练习
故意用大肠杆菌 O157:H7 感染苜蓿种子后发芽的场景,以测试卫生效果。
我们还将评估发芽率和芽苗产量,以评估我们的处理对芽苗质量的影响。
2 施加现实条件来准确反映豆芽的工业生产,以促进我们的采用
技术并吸引商业兴趣。
芽苗菜种子消毒不充分将继续危害食品供应的安全和保障,直到
SBIR一期项目的成功完成将带来一种新的生产方式。
将 ADM 技术扩展到其他种衣和食品加工领域。
设施表面将提高其他食品的安全性,未来的研究和开发将扩大这一范围。
ADM平台对人类健康和食品安全方面的其他应用的资助将确保食品安全。
通过减少食源性疾病的发生率来促进食品供应的完整性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Compel其他文献
William Compel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
CAPS1蛋白S259位点磷酸化介导胰岛神经预调控在β细胞头期分泌中的机制研究
- 批准号:82100838
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
阻断Cys259和DD介导的p75NTR信号通路延缓阿尔茨海默病进展的分子机制
- 批准号:
- 批准年份:2019
- 资助金额:55 万元
- 项目类别:面上项目
沙眼衣原体基因CT259在持续感染时的表达变化及功能初探
- 批准号:30600534
- 批准年份:2006
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PA21-259, PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical
PA21-259、PHS 2021-2 NIH、CDC 和 FDA 小型企业创新研究补助金申请综合征集(母版 SBIR [R43/R44] 临床
- 批准号:
10704207 - 财政年份:2022
- 资助金额:
$ 20万 - 项目类别:
99番元素Es標的を用いた重アクチノイド核の特異な核分裂機構の解明
使用 99 Es 靶材阐明重锕系元素核的独特裂变机制
- 批准号:
21H01098 - 财政年份:2021
- 资助金额:
$ 20万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
SBIR TOPIC 259: QUANTITATIVE TISSUE IMAGING FOR CLINICAL DIAGNOSIS AND PROGNOSIS
SBIR 主题 259:用于临床诊断和预后的定量组织成像
- 批准号:
7962742 - 财政年份:2009
- 资助金额:
$ 20万 - 项目类别:
EXC 259: Smart Interfaces - Understanding and Designing Fluid Boundaries
EXC 259:智能接口 - 理解和设计流体边界
- 批准号:
39072147 - 财政年份:2007
- 资助金额:
$ 20万 - 项目类别:
Clusters of Excellence